Werewolf Therapeutics (NASDAQ:HOWL), an innovative biopharmaceutical company developing "inducible" cytokines to treat cancer, today announced it has initiated a formal process to explore strategic alternatives.
Satellos Bioscience (NASDAQ:MSLE), a biotechnology company focused on developing small-molecule therapies that modulate muscle stem cell regeneration, reported its full-year 2025 financial results and provided updates on recent corporate and clinical milestones.
Humacyte (NASDAQ:HUMA), a pioneer in universally implantable, bioengineered human tissues, today announced its financial results for the fourth quarter and full year ended December 31, 2025.
Autolus Therapeutics (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today reported its financial results for the fourth quarter and full year ended December 31, 2025.
Super League (NASDAQ:SLE), a creator and publisher of content experiences and media solutions across the world’s largest immersive platforms, today reported record-breaking financial results for the fourth quarter and full year ended December 31, 2025.
51Talk Online Education Group (NYSE:COE), a leading global online English education platform, today announced its unaudited financial results for the fourth quarter and full year ended December 31, 2025.
LM Funding America (NASDAQ:LMFA), a cryptocurrency mining and specialty finance company, today announced its financial results for the fourth quarter and full year ended December 31, 2025.
BioXcel Therapeutics (NASDAQ:BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today reported its financial results for the fourth quarter and full year ended December 31, 2025.
Instil Bio (NASDAQ:TIL), a clinical-stage biopharmaceutical company, today reported its financial results for the fourth quarter and full year ended December 31, 2025, while outlining a transformative shift in its corporate strategy.
AstraZeneca (NASDAQ:AZN) today announced positive high-level results from the OBERON and TITANIA Phase III trials, marking a historic milestone in the treatment of chronic obstructive pulmonary disease (COPD).
Legence (NASDAQ:LGN), a preeminent integrated provider of energy efficiency and sustainability solutions for the built environment, today reported record-breaking financial results for the fourth quarter and full year ended December 31, 2025.
SBC Medical Group Holdings (NASDAQ:SBC), a leading Management Services Organization (MSO) for a diverse range of medical franchises, today announced its financial results for the fourth quarter and full fiscal year ended December 31, 2025.
